A 12 Month, Single-center, Non-randomized, Open-label Study of Outcomes of Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores in de Novo Renal Transplant Recipients.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 16 Aug 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 09 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jan 2018.